JP4799720B2 - Tableting punch with coating treatment - Google Patents
Tableting punch with coating treatment Download PDFInfo
- Publication number
- JP4799720B2 JP4799720B2 JP2000002652A JP2000002652A JP4799720B2 JP 4799720 B2 JP4799720 B2 JP 4799720B2 JP 2000002652 A JP2000002652 A JP 2000002652A JP 2000002652 A JP2000002652 A JP 2000002652A JP 4799720 B2 JP4799720 B2 JP 4799720B2
- Authority
- JP
- Japan
- Prior art keywords
- tableting
- punch
- tablets
- chrome
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011248 coating agent Substances 0.000 title claims description 17
- 238000000576 coating method Methods 0.000 title claims description 16
- 238000011282 treatment Methods 0.000 title claims description 3
- 239000000126 substance Substances 0.000 claims description 32
- 230000002378 acidificating effect Effects 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 230000001070 adhesive effect Effects 0.000 claims description 24
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 23
- 239000000853 adhesive Substances 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 150000005846 sugar alcohols Chemical class 0.000 claims description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
- 239000003905 agrochemical Substances 0.000 claims description 12
- 239000003337 fertilizer Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical group Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims description 10
- 229960002827 pioglitazone hydrochloride Drugs 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 239000003826 tablet Substances 0.000 description 45
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 26
- 239000000843 powder Substances 0.000 description 25
- 239000004570 mortar (masonry) Substances 0.000 description 22
- 229910045601 alloy Inorganic materials 0.000 description 19
- 239000000956 alloy Substances 0.000 description 19
- 238000005260 corrosion Methods 0.000 description 15
- 101150019161 SKS2 gene Proteins 0.000 description 14
- 230000007797 corrosion Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 229910001315 Tool steel Inorganic materials 0.000 description 12
- 229910052742 iron Inorganic materials 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 239000002831 pharmacologic agent Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- -1 2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007769 metal material Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000000832 lactitol Substances 0.000 description 3
- 235000010448 lactitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 3
- 229960003451 lactitol Drugs 0.000 description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000004071 soot Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GTJARIVVVORARS-TYYBGVCCSA-N (e)-but-2-enedioic acid;propan-2-one Chemical compound CC(C)=O.OC(=O)\C=C\C(O)=O GTJARIVVVORARS-TYYBGVCCSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229910000851 Alloy steel Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- CXOWYMLTGOFURZ-UHFFFAOYSA-N azanylidynechromium Chemical compound [Cr]#N CXOWYMLTGOFURZ-UHFFFAOYSA-N 0.000 description 1
- 239000010953 base metal Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960003090 seratrodast Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、例えば酸性の薬理作用物質、酸性の賦形剤などの酸性物質を含有する錠剤の製造に用いられ、優れた耐腐食性及び離型性を有する打錠用杵に関する。又、本発明は、例えば付着性のある薬理作用物質、付着性のある賦形剤(例えば糖アルコール)などの付着性物質を含有する錠剤の製造に用いられ、好適な離型性を有する打錠用杵に関する。
さらに本発明は、かかる打錠用杵を具有した打錠機、該打錠機を使用する錠剤の製造方法および該製造方法によって製造される錠剤に関する。
【0002】
【従来の技術】
一般の錠剤は、打錠機に設けられた杵と臼とを用いて打錠末を圧縮成型することにより打錠される。即ち、回転盤に付設された臼内に臼孔を形成し、臼孔の下方に配置した下杵の位置を調整して臼孔内の空間を所定容積に設定し、この臼孔内に粉末薬剤等の打錠末を収納したのち上杵で圧縮して錠剤を形成し、その後、下杵で押し上げて上記錠剤を臼孔内から取り出すように構成してある。
上記の杵は、頻繁に繰り返される上記圧縮操作で容易に変形してはならないことから高い機械的強度が要求され、従来は超鋼合金や合金工具鋼を用いて形成されており、さらに腐食対策として杵表面にクロムメッキ等を施したものも使用されている。
【0003】
【発明が解決しようとする課題】
上記合金工具鋼などを用いた従来の杵は、その金属材料が基本的に腐食される性質を有しており、特に打錠用末が酸性薬物等の酸性物質を含む場合、これを打錠するときは上記金属材料の腐食が一層進行しやすく、打錠中に腐食が開始する虞がある。
これらの腐食が杵に発生すると、表面の滑り性や打錠末との離型性が低下し、錠剤を臼孔から取り出し難くなるうえ、上記腐食により生じた異物が錠剤に混入する虞もある。
【0004】
また、打錠末と杵の表面の離型性が悪い場合は、杵の表面に打錠末が付着して打錠された錠剤表面が粗面になったり、錠剤表面に明瞭な刻印を形成できなくなったりする等の問題が生じる。
本発明は、上記問題点を解消し、特に、酸性薬物等の酸性物質を含有する製剤について錠剤を成型するための打錠機に好適な、優れた耐腐食性と離型性を有する打錠用杵を提供することを技術的課題とする。
【0005】
又さらに、上記合金工具鋼などを用いた従来の件は、その金属材料が基本的に表面に打錠末が付着する性質を有しており、特に打錠用末が例えば付着性のある薬理作用物質、付着性のある賦形剤(例えば糖アルコール)などの付着性物質を含む場合これを打錠するときは上記金属材料への付着が一層進行しやすい。これらの付着が杵に発生すると打錠末と杵の表面の離型性が悪くなり、打錠された錠剤表面が粗面になったり、錠剤表面に明瞭な刻印を形成できなくなったりする等の問題が生じる。
本発明は、上記問題点を解消し、特に、例えば付着性のある薬理作用物質、付着性のある賦形剤(例えば糖アルコール)などの付着性物質を含有する製剤について錠剤を成型するための打錠機に好適な、優れた離型性を有する打錠用杵を提供することを技術的課題とする。
【0006】
【課題を解決するための手段】
本発明者らは、上記課題を解決するために、鋭意検討を行った結果、母材(たとえば合金工具鋼)にクロームドッペ−N(Cr-Dope'-N、登録商標、以下同じ。)でコーティングを施した杵は優れた耐腐食性及び離型性を有するとの予想外の新知見を得、さらに検討を重ねて、本発明を完成するに至った。
【0007】
すなわち、本発明は、
(1)医薬品と農薬と肥料と食品とのいずれかである錠剤の製造に用いる、クロームドッペ−Nでコーティング表面処理した打錠用杵、
(2)医薬品と農薬と肥料と食品とのいずれかである錠剤の製造に用いる、クロームドッペ−Nコーティングで表面を耐腐食処理した打錠用杵、
(3)医薬品と農薬と肥料と食品とのいずれかである錠剤の製造に用いる、クロームドッペ−Nコーティングで表面を離型処理した打錠用杵、
(4)医薬品と農薬と肥料と食品とのいずれかである錠剤の製造に用いる、クロームドッペ−Nコーティングで表面を付着防止処理した打錠用杵、
(5)酸性物質又は付着生物質を含有する錠剤を成形するための打錠機(1)に用いる杵(4、6)に適用した前記(1)の打錠用杵、
(6)酸性物質が塩酸ピオグリタゾンである前記(5)の打錠用杵、
(7)付着性物質が糖アルコールである前記(5)の打錠用杵、
(8)糖アルコールがD−マンニトールである前記(7)の打錠用杵、
(9)医薬品と農薬と肥料と食品とのいずれかである錠剤の製造に用いる打錠機であって、クロームドッペ−Nでコーティング処理した杵を具用することを特徴とする打錠機、
(10)前記(9)の打錠機を使用することを特徴とする錠剤の製造方法、
(11)錠剤が酸性物質又は付着性物質を含有する前記(10)の製造方法、
(12)酸性物質が塩酸ピオグリタゾンである前記(11)の製造方法、
(13)付着性物質が糖アルコールである前記(11)の錠剤の製造方法、及び
(14)糖アルコールがD−マンニトールである前記(13)の製造方法、
に関する。
【0008】
本発明の打錠用杵の原料として用いられる母材は従来技術において、打錠用杵材として用いられるものはどのようなものでもよく、具体的には例えば、超硬合金、合金工具鋼、燒結合金など頻繁に繰り返される圧縮操作で容易に変形せず高い機械的高度を有するものであればどのようなものでもよく、より具体的には、SKS2、SKD、NHアロイ、SUS440Cなどが挙げられるが、SKS2が最も好ましい。
【0009】
さらに詳論すれば、鉄を95%、クロムを1%、タングステンを1.5%、炭素1%、ケイ素を0.35%、マンガンを0.8%、リンを0.03%、イオウを0.03%(%はいずれも重量比、以下も同じ)を含む合金工具鋼で製造したSKS2やコバルトを36〜53%、クロムを27〜35%、タングステンを10〜20%、炭素を2〜3%含有する成分にタンタルとニオブの少なくともいずれか一方を0.2〜5%加え、さらに所望によって鉄を1〜5%、ケイ素を1〜3%加え、必要な場合さらにニッケルを5%以下を加えたことを特徴とする燒結合金等が好ましい。
【0010】
母材のクロームドッペ−Nによるコーティングは自体公知の方法、例えば物理蒸着技術の一種であるスパッタリング法によって行うことができ、より具体的には例えば型技術第8巻第5号(1993年4月号)第70〜78頁に記載された方法によって容易に行われる。
【0011】
本発明における錠剤は、医薬品に限らず、農薬、肥料、食品、プラスチック、セラミック、金属などを含む。これらの錠剤は例えば医薬における薬理活性成分のように生理活性成分を含む場合が多く、薬理活性成分はどのようなものでもよい。薬理活性成分は特に限定されない。医薬用途の酸性物質、例えば酸性薬物としては、具体的には塩酸ピオグリタゾン、塩酸マニジピン、塩酸デラプリル、塩酸フルスルチアミン、塩酸セフォチアムヘキセチル、塩酸チアミン、塩酸ヒドロキシジンなどが挙げられる。これら酸性薬物は自体公知の手段に従って容易に製造される。
【0012】
また、さらに、本発明における酸性薬物は例えば酸性薬物と中性薬物の混合物であってよく、要するに本発明における酸性薬物は酸性を示す固形物質であればどのようなものでもよい。
【0013】
本発明に使用する打錠末は付着性物質を含む。そのような付着性物質として付着性薬理活性成分、付着性のある賦形剤(例えば糖アルコール)が挙げられる。付着性のある薬理活性成分として、例えば3−〔1−(フェニルメチル)ピペリジンー4−イル〕−1−(2,3,4,5−テトラヒドロー1H−1−ベンズアゼピン−8−イル)−1−プロパノン フマレート、リセドロネート、塩酸ピオグリタゾン等が例示される。又さらに打錠末に付着性のある賦形剤が含まれるとき、薬理活性成分は付着性がなくてもよい。付着性がなくても本発明に使用されてよい薬理活性成分としては、例えばランソプラゾール、塩酸マニジピン、塩酸デラプリル、カンデサルタンシレキセチル、ビンポセチン、セラトロダスト等が挙げられる。
従って、錠剤を製造する場合は、上記薬理活性成分以外に例えば賦形剤あるいは結合剤として杵に付着性がある糖アルコールが打錠末原料として使用される。
【0014】
糖アルコールも医薬用途のみならず、農薬、肥料、食品、プラスチック、セラミック、金属の分野で使用される糖アルコールを含む。医薬用途の糖アルコールとしては、具体的にはエリスリトール、D−マンニトール、D−ソルビトール、キシリトール、マルチトール、無水マルトース、含水マルトース、無水ラクチトール、無水マルト−ス、含水マルトース、無水ラクチトール、含水ラクチトール、還元麦芽糖水アメが挙げられる。
また、複数の糖アルコールを組み合わせて用いることもできる。
なお、上記の例示(例えば塩酸ピオグリタゾン)から明らかなように、酸性物質であり同時に付着性物質である物質も本発明で便宜に使用される。
【0015】
錠剤はいわゆる錠剤の形状を有する物ならどのようなものでもよく、薬物を含有する細粒、ペレット等を包含する錠剤であってよいことは言うまでもない。
かかる錠剤を製造する場合、通常上記薬理活性成分(薬物)は賦形剤、滑沢剤、崩壌剤などと混合して打錠末となしこれを杵と臼で圧縮されて錠剤が製造される。本発明においては、通常は例えば糖アルコール又は付着性を有する薬物が打錠末に含有されている。このようにして得られる錠剤を常法に従ってさらに表面コーティングして製品としてもよい。また錠剤には必要に応じて、防腐剤、抗酸化剤、着色剤、甘味剤、香料、フレーバーなどの製剤添加剤を打錠末に配合することもできる。
【0016】
賦形剤の好適な例としては、例えば乳糖、白糖などの糖類、D−マンニトール、D−ソルビトールなどの糖アルコール、デンプン(例えばトウモロコシデンプン、バレイショデンプン、小麦デンプンなど)、α化デンプン、デキストリン、結晶セルロース、低置換度ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、アラビアゴム、デキストリン、プルラン、軽質無水ケイ酸、合成ケイ酸アルミニウム、カルボキシメチルセルロースカルシウム、メタケイ酸アルミン酸マグネシウムなどが挙げられる。
【0017】
滑沢剤の好適な例としては、例えばステアリン酸マグネシウム、ステアリン酸カルシウム、タルク、コロイドシリカなどが挙げられる。
【0018】
結合剤の好適な例としては、例えばデンプン、α化デンプン、ショ糖、ゼラチン、アラビアゴム、メチルセルロース、カルボキシメチルセルロース、カルボキシメチルセルロースナトリウム、結晶セルロース、白糖、D−マンニトール、トレハロース、デキストリン、プルラン、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドンなどが挙げられる。
【0019】
崩壊剤の好適な例としては、例えばデンプン、α化デンプン、カルボキシメチルセルロース、カルボキシメチルセルロースカルシウム、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスポビドン、軽質無水ケイ酸、低置換度ヒドロキシプロピルセルロースなどが挙げられる。
【0020】
コーティング剤としては、例えばヒドロキシプロピルメチルセルロース、エチルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルセルロース、ポリオキシエチレングリコール、ツイーン80、プルロニックF68,ヒマシ油、セルロースアセテートフタレート、ヒドロキシメチルセルロースアセテートサクシネート、オイドラキット(ローム社製、西ドイツ、アクリル酸系共重合物)、カルボキシメチルエチルセルロース、ポルビニルアセタルジエチルアミノアセテート、ワックス類およびタルク、酸化チタン、ベンガラ等の色素などが挙げられる。
【0021】
酸味料としては、例えばクエン酸(無水クエン酸)、酒石酸、リンゴ酸などが挙げられる。
人工甘味料としては、例えばサッカリンナトリウム、グリチルリチンニカリウム、アスパルテーム、ステビア、ソーマチンなどが挙げられる。
香料としては、合成物および天然物のいずれでもよく、例えばレモン、ライム、オレンジ、メントール、ストロベリーなどが挙げられる。
着色剤としては、例えば食用黄色5号、食用赤色2号、食用青色2号などの食用色素、食用レーキ色素、ベンガラ、タルク、タール系色素などが挙げられる。
【0022】
打錠末中の酸性薬物等の酸性物質の使用割合は、一概に言えず広範囲に渉る。具体的に約0.001〜99.5%、より好ましくは約0.01〜70%、最も好ましくは約0.1〜50%程度である。
打錠圧は通常は約0.1〜3.0トン/杵程度、好ましくは0.5〜3.0トン/杵程度であり、さらに好ましくは0.8〜1.6トン/杵程度である。
臼の内径は通常は約3〜20mm程度、好ましくは約3〜13mm程度、さらに好ましくは5〜9mm程度である。臼の形状は円形でもよいし、オーバル、オブロングなど異形の場合もある。
【0023】
打錠末中の糖アルコールの使用割合は、一概に言えず広範囲に渉る。具体的に約0.001〜99.5%、より好ましくは約0.01〜90%、最も好ましくは約0.1〜90%程度である。
打錠圧は通常は約0.1〜3.0トン/杵程度であり、好ましくは0.8〜1.6トン/杵程度である。
臼の内径は通常は約3〜20mm程度、好ましくは5〜13mm程度である。臼の形状は円形でもよいし、オーバル、オブロングなど異形の場合もある。
【0024】
【発明の実施の形態】
以下、本発明の実施の形態を図面に基づき説明する。
図1は、本発明の実施形態の杵を用いた回転式打錠機の概略断面図である。図1に示すように、この回転式打錠機(1)の回転盤(2)には、周方向に所定間隔をおいて複数の臼を配置してあり、この臼(3)内に臼孔(3a)を形成してある。
【0025】
この臼孔(3a)の上方には、上杵(4)を臼孔(3a)に対して上下動可能に上杵保持盤(5)に保持してある。また、臼孔(3a)の下方には下杵(6)を保持盤(7)に上下動可能に保持し、この下杵(6)の杵先を臼孔(3a)内に下方から突入させてある。
【0026】
上記上杵(4)の上方には、上杵(4)の上端に設けた頭部と接触するように上杵ガイドレール(8)を配置してあり、一方、下杵(6)の下方には、下杵(6)の下端に設けた頭部と接触するように下杵ガイドレール(9)を配置してある。そして、上記回転盤(2)と上杵保持盤(5)及び下杵保持盤(7)は同軸に回転駆動され、この回転により上杵(4)と下杵(6)はそれぞれ両ガイドレール(8・9)に案内されて所定位置で上下に駆動される。
上記上杵(4)と下杵(6)とは、いずれも合金工具鋼にクロームドッペ−Nコーティングを施してある。
【0027】
上記回転式打錠機では次の手順で錠剤が打錠される。
最初に、下杵ガイドレール(9)により下杵(6)が所定高さに位置決めされて臼孔(3a)内の空間が所定容積に設定され、充填ゾーンにおいてこの臼孔(3a)内に打錠末(10)が充填される。次いで、圧縮ゾーンにおいて上杵(4)が上杵ガイドレール(8)に案内され下方へ移動して圧縮ローラに導かれ、上記打錠末(10)が圧縮されることにより打錠される。
【0028】
その後、上杵ガイドレール(8)に案内されて上杵(4)が持ち上げられ、取り出しゾーンにおいて下杵(6)が下杵ガイドレール(9)により押し上げられ、臼孔(3a)から上記圧縮成型された錠剤が取り出される。
次に、上記クロームドッペ−Nコーティングを施した杵の酸性薬物を含有する製剤に対する耐腐食性及び離型性と当該N−クロームドッペ−Nコーティングを施した杵の糖アルコールを含有する製剤に対する離型性を、従来の合金工具鋼および合金工具鋼にコーティングを施した杵等の耐腐食性、離型性と比較しながら説明する。
【0029】
【実施例】
〔実施例1〕
従来の合金工具鋼からなる杵(以下SKS2)に上記の自体公知の手段(型技術第8巻第5号(1993年4月号)第70〜78頁参照)に従ってクロームドッペ−Nコーティングを施して杵(以下単に実施例杵ともいう)を得た。
上記のクロームドッペ−Nコーティングを施した杵の腐食性をSKS2、燒結合金(以下アロイ)およびSKS2にコーティングを施した杵と比較した。結果は表1に示す通りであった。SKS2杵は保管(RH75%、室温、3日間)時に腐食を生じ、塩酸ピオグリタゾンを27.55%含有する打錠末(塩酸ピオグリタゾン33.06重量部、乳糖76.34重量部、ヒドロキシプロピルセルロース3.0重量部、カルボキシメチルセルロースカルシウム7.2重量部およびステアリン酸マグネシウム0.4重量部を混合して得た)との接触により腐食が大きく加速された。窒化チタン(以下、TiN)コーティング杵は打錠末との接触により部分的に腐食を生じた。一方、実施例杵、アロイ杵、クロムメッキ杵、窒化クロム(以下、CrN)コーティング杵は全く腐食されなかった。
【0030】
なお、比較に用いた杵は以下のものを使用した。
a) SKS2杵:鉄を95%、クロムを1%、タングステンを1.5%、炭素を1%、ケイ素を0.35%、マンガンを0.8%、リンを0.03%、イオウを0.03%含む合金工具鋼で製造したもの。
b) アロイ杵 :耐腐食性に優れた燒結合金(特願平09−323123号)で製造したもの。
c) クロムメッキ杵、TiNコーティング杵およびCrNコーティング杵
:SKS2杵に公知手段に従ってそれぞれクロムメッキ、TiNコーティングおよびCrNコーティングを施して製造したもの。
【0031】
【表1】
【0032】
次に上記の杵の離型性を打錠時に発生する杵の表面に打錠末が付着して錠剤表面に明瞭な刻印を形成しない錠剤(以下刻印不良)の発生状況にて評価した。上記の塩酸ピオグリタゾン27.55%含有する打錠末を用いて上記と同様の杵を対照に比較した。結果は表2に示す通りとなり、クロムメッキ杵、TiNコーティング杵およびCrNコーティング杵は打錠初期から刻印不良が発生し、打錠不可となったのに対し、実施例杵、SKS2杵およびアロイ杵は打錠初期及び終期においても刻印不良の発生は認められなかった。
【0033】
【表2】
【0034】
表1、2より耐腐食性、離型性ともに満足するものはクロームドッペ−Nコーティング杵(実施例杵)とアロイ杵であることがわかった。ただし、アロイ杵については、長時間打錠した際に杵先に亀裂が入り強度面で杵への適用は困難であった。
なお、ダイアモンドライクカーボン(DLC)、ニウロイ96処理等の他の表面処理もSKS2杵に試みたが満足な結果を得ることができなった。
【0035】
〔実施例2〕
従来の合金工具からなる杵(以下SKS2)に上記の自体公知の手段(型技術第8巻第5号(1993年4月号)第70〜78頁参照)に従ってクロームドッペ−Nコーティングを施して杵(以下単に実施例杵ともいう)を得た。上記実施例杵の離型性をSKS2で製造した杵、SUS440Cで製造した杵およびSKS2にダイヤモンド・ライク・カーボン(DLC)コーティングを施した杵とを比較した。杵の離型性を、打錠時に発生する杵の表面に打錠末が付着して錠剤表面に明瞭な刻印を形成しない錠剤(以下刻印不良)の発生状況および杵表面への打錠末の付着(以下杵付着不良)発生状況にて評価した。なお、この打錠の実施においてD−マンニトールを含有する下記の処方の打錠末を用いた。
【0036】
【0037】
結果は表3に示す通りとなり、SKS2杵、SUS440C杵およびDLCコーティング杵は打錠初期から刻印不良が発生し、打錠不可となったのに対し、実施例杵は打錠初期及び終期においても刻印不良の発生は認められず、杵表面への打錠末の付着発生も認められなかった。
【0038】
【表3】
【0039】
〔実施例3〕
ランソプラゾール30重量部を含有するランソプラゾール細粒(日本特許出願特願平11−135177に記載の方法により製造した) 270重量部、D−マンニトール 204重量部、L−HPC−33 30重量部、セオラスKG−801 30重量部、クロスポビドン 15重量部、無水クエン酸 3重量部、アスパルテーム 9重量部、ストロベリ−D 3重量部およびステアリン酸マグネシウム 6重量部を混合して得られる打錠末を図1で示される打錠機で打錠した。杵材質および杵の表面処理は実施例1と同一である。打錠条件は打錠外径7mmφ、重量180mg/錠、打圧0.57tonであった。杵材質・表面処理、20000錠/杵打錠時の結果は下記表4のとおりであった。
【0040】
【表4】
【0041】
【発明の効果】
本発明の合金工具鋼にクロームドッペ−Nコーティングを施した杵は、酸性物質を含有する製剤の打錠において優れた耐腐食性と離型性を示し、付着性物質を含有する製剤の打錠において、離型性に優れ、安定した工業的生産に適した打錠を提供する。
【0042】
【図面の簡単な説明】
【図1】本発明の実施形態の杵を用いた、回転式打錠機の概略断面図である。
[符号の説明]
1………………回転式打錠機、
2………………回転盤、
3………………臼、
3a……………臼孔、
4………………上杵、
5………………上杵保持盤、
6………………下杵、
7………………下杵保持盤、
8………………上杵ガイドレール、
9………………下杵ガイドレール、
10……………打錠末[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a tablet punch for use in the production of tablets containing acidic substances such as acidic pharmacologically active substances and acidic excipients and having excellent corrosion resistance and releasability. In addition, the present invention is used for the production of tablets containing adhesive substances such as adhesive pharmacological substances and adhesive excipients (for example, sugar alcohols), and has a suitable release property. It relates to a lock bag.
Furthermore, the present invention relates to a tableting machine having such a tableting punch, a tablet manufacturing method using the tableting machine, and a tablet manufactured by the manufacturing method.
[0002]
[Prior art]
A general tablet is tableted by compressing and molding a tableting powder using a punch and a mortar provided in a tableting machine. That is, a mortar hole is formed in a mortar attached to the rotating disk, and the position of the lower punch placed under the mortar hole is adjusted to set the space in the mortar hole to a predetermined volume. After storing the tableting powder such as a medicine, it is compressed with an upper punch to form a tablet, and then pushed up with a lower punch to take out the tablet from the mortar.
The above-mentioned flaws must not be easily deformed by the above-described repeated compression operation, so high mechanical strength is required. Conventionally, they have been formed using super steel alloy or alloy tool steel, and are also used as a countermeasure against corrosion. As an example, a chrome-plated surface is used.
[0003]
[Problems to be solved by the invention]
The conventional scissors using the above-mentioned alloy tool steel have the property that the metal material is basically corroded, especially when the powder for tableting contains an acidic substance such as an acidic drug. When doing so, the corrosion of the metal material is more likely to proceed, and there is a possibility that the corrosion starts during tableting.
When these corrosions occur in the wrinkles, the surface slipperiness and releasability from the tableting powder are lowered, and it is difficult to take out the tablets from the mortar, and foreign substances generated by the corrosion may be mixed into the tablets. .
[0004]
In addition, when the release properties of the tableting powder and the surface of the punch are poor, the tableting powder adheres to the surface of the tablet and the tablet surface becomes rough, or a clear marking is formed on the tablet surface. Problems such as being unable to do so occur.
The present invention solves the above-mentioned problems, and particularly has excellent corrosion resistance and release properties suitable for a tableting machine for molding tablets for preparations containing acidic substances such as acidic drugs. It is a technical challenge to provide a vase.
[0005]
Furthermore, the conventional case using the above-mentioned alloy tool steel has the property that the metal material basically has a tableting powder adhering to the surface. When an adhesive substance such as an active substance or an adhesive excipient (for example, sugar alcohol) is included, adhesion to the metal material is more likely to proceed when tableting. When such adhesion occurs in the wrinkle, the release properties of the tableting powder and the surface of the wrinkle are deteriorated, and the tableted tablet surface becomes rough, or a clear inscription cannot be formed on the tablet surface. Problems arise.
The present invention solves the above-mentioned problems, and in particular, for molding a tablet for a preparation containing an adhesive substance such as an adhesive pharmacological agent and an adhesive excipient (for example, sugar alcohol). A technical problem is to provide a tableting punch suitable for a tableting machine and having excellent releasability.
[0006]
[Means for Solving the Problems]
As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that the base metal (for example, alloy tool steel) is Chrome Dope-N (Cr-Dope'-N , registered trademark, the same shall apply hereinafter ) . The unexpected new knowledge that the coated soot has excellent corrosion resistance and mold release properties has been obtained, and further studies have been made to complete the present invention.
[0007]
That is, the present invention
(1) A tableting punch coated with a surface coated with Chrome Doppe-N, which is used in the manufacture of tablets that are any of pharmaceuticals, agricultural chemicals, fertilizers and foods,
(2) A tableting punch whose surface is anti-corrosion-treated with a Chrome Dope-N coating, which is used for manufacturing tablets that are any of pharmaceuticals, agricultural chemicals, fertilizers and foods,
(3) A tableting punch having a surface release-treated with a chrome dope-N coating, which is used for manufacturing tablets that are any of pharmaceuticals, agricultural chemicals, fertilizers and foods,
(4) A tableting punch whose surface is treated to prevent adhesion with a chrome doppe-N coating, which is used in the manufacture of tablets that are any of pharmaceuticals, agricultural chemicals, fertilizers and foods,
(5) The tableting punch of the above (1) applied to the punch (4, 6) used in the tableting machine (1) for forming a tablet containing an acidic substance or an adherent biomaterial,
(6) The tableting punch of the above (5), wherein the acidic substance is pioglitazone hydrochloride,
(7) The tableting punch of (5), wherein the adhesive substance is a sugar alcohol;
(8) The tableting punch according to (7), wherein the sugar alcohol is D-mannitol,
(9) A tableting machine used for the manufacture of tablets that are any one of pharmaceuticals, agricultural chemicals, fertilizers and foods, characterized by using a punch coated with Chrome Doppe-N,
(10) A tablet production method using the tableting machine of (9),
(11) The production method of the above (10), wherein the tablet contains an acidic substance or an adhesive substance,
(12) The production method of the above (11), wherein the acidic substance is pioglitazone hydrochloride,
The method of manufacturing a tablet of the (13) with wear material is a sugar alcohol (11), and (14) producing how the sugar alcohol is D- mannitol (13),
About.
[0008]
The base material used as a raw material for the tableting punch of the present invention may be any material used as a tableting punch in the prior art, specifically, for example, cemented carbide, alloy tool steel, Any material may be used as long as it has a high mechanical altitude and is not easily deformed by a frequently repeated compression operation such as a gold bond, and more specifically, SKS2, SKD, NH alloy, SUS440C, etc. However, SKS2 is most preferable.
[0009]
More specifically, 95% iron, 1% chromium, 1.5% tungsten, 1% carbon, 0.35% silicon, 0.8% manganese, 0.03% phosphorus, 0% sulfur. SKS2 and cobalt manufactured with alloy tool steel containing 0.03% (% is weight ratio, the same applies below) 36 to 53% of cobalt, 27 to 35% of chromium, 10 to 20% of tungsten, 2 to 2 of carbon Add 0.2-5% of at least one of tantalum and niobium to the component containing 3%, further add 1-5% of iron and 1-3% of silicon as required, and if necessary, further add 5% or less of nickel A spear bond gold or the like characterized by adding
[0010]
Coating of the base material with chrome doppe-N can be performed by a method known per se, for example, a sputtering method which is a kind of physical vapor deposition technology. More specifically, for example, die technology Vol. 8 No. 5 (April 1993). No.) It is easily carried out by the method described on pages 70-78.
[0011]
The tablets in the present invention are not limited to pharmaceuticals, but include agricultural chemicals, fertilizers, foods, plastics, ceramics, metals, and the like. These tablets often contain physiologically active ingredients such as pharmacologically active ingredients in medicine, and any pharmacologically active ingredient may be used. The pharmacologically active ingredient is not particularly limited. Specific examples of acidic substances for pharmaceutical use, such as acidic drugs, include pioglitazone hydrochloride, manidipine hydrochloride, delapril hydrochloride, fursultiamine hydrochloride, cefotium hexetyl hydrochloride, thiamine hydrochloride, and hydroxyzine hydrochloride. These acidic drugs are easily produced according to a method known per se.
[0012]
Furthermore, the acidic drug in the present invention may be, for example, a mixture of an acidic drug and a neutral drug. In short, the acidic drug in the present invention may be any solid substance that exhibits acidity.
[0013]
The tableting powder used in the present invention contains an adhesive substance. Examples of such an adhesive substance include an adhesive pharmacologically active ingredient and an adhesive excipient (for example, sugar alcohol). For example, 3- [1- (phenylmethyl) piperidin-4-yl] -1- (2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl) -1- Examples include propanone fumarate, risedronate, and pioglitazone hydrochloride. Further, when the tableting powder contains an adhesive excipient, the pharmacologically active ingredient may not be adhesive. Examples of the pharmacologically active ingredient that may be used in the present invention without adhesion are lansoprazole, manidipine hydrochloride, delapril hydrochloride, candesartan cilexetil, vinpocetine, seratrodast and the like.
Therefore, when manufacturing a tablet, in addition to the above-mentioned pharmacologically active ingredients, for example, a sugar alcohol having an adhesive property to a bag as an excipient or a binder is used as a raw material for tableting.
[0014]
Sugar alcohols include sugar alcohols used in the fields of agricultural chemicals, fertilizers, foods, plastics, ceramics and metals as well as pharmaceutical applications. Specific examples of sugar alcohols for pharmaceutical use include erythritol, D-mannitol, D-sorbitol, xylitol, maltitol, anhydrous maltose, hydrous maltose, anhydrous lactitol, anhydrous maltose, hydrous maltose, anhydrous lactitol, hydrous lactitol, Reduced maltose water candy is mentioned.
Also, a plurality of sugar alcohols can be used in combination.
As is clear from the above examples (for example, pioglitazone hydrochloride), a substance that is both an acidic substance and an adhesive substance is also used in the present invention for convenience.
[0015]
It is needless to say that the tablet may be anything having a so-called tablet shape, and may be a tablet including fine granules, pellets and the like containing the drug.
When producing such tablets, the above-mentioned pharmacologically active ingredients (drugs) are usually mixed with excipients, lubricants, disintegrants, etc. to form a tableting powder, which is compressed with a pestle and a mortar to produce tablets. The In the present invention, for example, a sugar alcohol or an adhesive drug is usually contained in the tableting powder. The tablet thus obtained may be further surface-coated according to a conventional method to obtain a product. In addition, prescription additives such as preservatives, antioxidants, coloring agents, sweeteners, fragrances, flavors and the like can be added to the tablet as needed.
[0016]
Suitable examples of excipients include sugars such as lactose and sucrose, sugar alcohols such as D-mannitol and D-sorbitol, starch (eg corn starch, potato starch, wheat starch etc.), pregelatinized starch, dextrin, Examples thereof include crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, dextrin, pullulan, light anhydrous silicic acid, synthetic aluminum silicate, calcium carboxymethylcellulose, and magnesium aluminate metasilicate.
[0017]
Preferable examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
[0018]
Preferable examples of the binder include starch, pregelatinized starch, sucrose, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropyl. Examples thereof include cellulose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.
[0019]
Preferable examples of the disintegrant include starch, pregelatinized starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, crospovidone, light anhydrous silicic acid, low-substituted hydroxypropyl cellulose and the like. It is done.
[0020]
Examples of the coating agent include hydroxypropylmethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyoxyethylene glycol, Tween 80, Pluronic F68, castor oil, cellulose acetate phthalate, hydroxymethylcellulose acetate succinate, Eudrakit (Rohm, West Germany) Acrylic acid copolymer), carboxymethyl ethyl cellulose, porvinyl acetal diethylaminoacetate, waxes and pigments such as talc, titanium oxide, and bengara.
[0021]
Examples of the acidulant include citric acid (anhydrous citric acid), tartaric acid, malic acid and the like.
Examples of the artificial sweetener include saccharin sodium, glycyrrhizin dipotassium, aspartame, stevia, thaumatin and the like.
As a fragrance | flavor, any of a synthetic material and a natural product may be sufficient, for example, lemon, lime, orange, menthol, strawberry, etc. are mentioned.
Examples of the colorant include edible dyes such as edible yellow No. 5, edible red No. 2 and edible blue No. 2, edible lake dyes, bengara, talc, and tar dyes.
[0022]
The rate of use of acidic substances such as acidic drugs in tableting powders is unclear and varies widely. Specifically, it is about 0.001 to 99.5%, more preferably about 0.01 to 70%, and most preferably about 0.1 to 50%.
The tableting pressure is usually about 0.1 to 3.0 ton / 杵, preferably about 0.5 to 3.0 ton / 杵, and more preferably about 0.8 to 1.6 ton / 杵. is there.
The inner diameter of the mortar is usually about 3 to 20 mm, preferably about 3 to 13 mm, and more preferably about 5 to 9 mm. The shape of the mortar may be circular or may be irregular such as an oval or oblong.
[0023]
The proportion of sugar alcohol used in the tableting powder is unclear and varies widely. Specifically, it is about 0.001 to 99.5%, more preferably about 0.01 to 90%, and most preferably about 0.1 to 90%.
The tableting pressure is usually about 0.1 to 3.0 tons / 杵, preferably about 0.8 to 1.6 tons / 杵.
The inner diameter of the mortar is usually about 3 to 20 mm, preferably about 5 to 13 mm. The shape of the mortar may be circular or may be irregular such as an oval or oblong.
[0024]
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, embodiments of the present invention will be described with reference to the drawings.
FIG. 1 is a schematic cross-sectional view of a rotary tableting machine using a punch according to an embodiment of the present invention. As shown in FIG. 1, a plurality of mortars are arranged at predetermined intervals in the circumferential direction on the rotary disk (2) of the rotary tableting machine (1), and the mortars are placed in the mortar (3). A hole (3a) is formed.
[0025]
Above the mortar hole (3a), the upper ridge (4) is held on the upper ridge holding plate (5) so as to be movable up and down with respect to the mortar hole (3a). Also, below the mortar hole (3a), a lower punch (6) is held on the holding disc (7) so as to be movable up and down, and the tip of the lower punch (6) enters the mortar hole (3a) from below. I'm allowed.
[0026]
Above the upper rod (4), an upper rod guide rail (8) is arranged so as to come into contact with the head provided at the upper end of the upper rod (4), while below the lower rod (6). The lower heel guide rail (9) is arranged so as to contact the head provided at the lower end of the lower heel (6). The rotating plate (2), the upper rod holding plate (5) and the lower rod holding plate (7) are rotationally driven coaxially, and this rotation causes the upper rod (4) and the lower rod (6) to both guide rails. Guided by (8, 9), it is driven up and down at a predetermined position.
The upper iron (4) and the lower iron (6) are both coated with chrome doppe-N coating on alloy tool steel.
[0027]
In the rotary tableting machine, tablets are tableted by the following procedure.
First, the lower armpit (6) is positioned at a predetermined height by the lower armpit guide rail (9), and the space in the mortar hole (3a) is set to a predetermined volume, and in this mortar hole (3a) in the filling zone. The tableting powder (10) is filled. Next, in the compression zone, the upper punch (4) is guided by the upper guide rail (8), moved downward and guided to the compression roller, and the tableting powder (10) is compressed to be compressed.
[0028]
Thereafter, the upper guide (4) is guided by the upper guide rail (8), and the lower guide (6) is pushed up by the lower guide guide rail (9) in the take-out zone, and is compressed from the mortar hole (3a). The molded tablet is taken out.
Next, the corrosion resistance and releasability for the preparation containing the acidic drug of candy coated with Chrome Doppe-N and the release for the preparation containing sugar alcohol of the candy coated with N-chrome Doppe-N. The moldability will be described in comparison with the conventional alloy tool steel and the corrosion resistance and releasability of the heel coated with the alloy tool steel.
[0029]
【Example】
[Example 1]
A chrome doppe-N coating is applied to the conventional alloy tool steel (hereinafter referred to as SKS2) according to the above-mentioned means known per se (see Mold Technology Vol. 8 No. 5 (April 1993) pp. 70-78). To obtain cocoon (hereinafter also simply referred to as Example 杵).
The corrosivity of the cocoons coated with the above Chrome Doppe-N coating was compared with that of cocoons coated with SKS2, cocoon bonding gold (alloy) and SKS2. The results were as shown in Table 1. SKS2 杵 was corroded during storage (RH 75%, room temperature, 3 days), and tableted powder containing 27.55% pioglitazone hydrochloride (33.06 parts by weight pioglitazone hydrochloride, 76.34 parts by weight lactose, hydroxypropylcellulose 3 Corrosion was greatly accelerated by contact with 0.0 parts by weight, 7.2 parts by weight of carboxymethylcellulose calcium and 0.4 parts by weight of magnesium stearate). The titanium nitride (hereinafter, TiN) coated wrinkles were partially corroded by contact with the tableting powder. On the other hand, Example 杵, Alloy 杵, Chromium plating 杵 and Chromium nitride (hereinafter referred to as CrN) coating 杵 were not corroded at all.
[0030]
The followings were used for the comparison.
a) SKS2 杵: 95% iron, 1% chromium, 1.5% tungsten, 1% carbon, 0.35% silicon, 0.8% manganese, 0.03% phosphorus, sulfur Made of alloy tool steel containing 0.03%.
b) Alloy iron: manufactured with a gold bond gold excellent in corrosion resistance (Japanese Patent Application No. 09-323123).
c) Chrome-plated iron, TiN-coated iron and CrN-coated iron: manufactured by applying chrome-plated, TiN-coated and CrN-coated to SKS2 steel according to known methods, respectively.
[0031]
[Table 1]
[0032]
Next, the releasability of the above-mentioned wrinkles was evaluated in terms of the occurrence of tablets (hereinafter referred to as imprinting defects) in which a tableting powder adhered to the surface of the wrinkles generated during tableting and no clear marking was formed on the tablet surface. Using the tableting powder containing 27.55% of the above pioglitazone hydrochloride, the same wrinkles as described above were compared with the control. The results are shown in Table 2. The chrome-plated iron, TiN-coated iron and CrN-coated iron had imprinting defects from the initial stage of tableting and were unable to be tableted. In the initial and final tableting, no imprinting was observed.
[0033]
[Table 2]
[0034]
From Tables 1 and 2, it was found that the ones satisfying both the corrosion resistance and the releasability were the Chrome Doppe-N coating cage (Example IV) and the alloy cage. However, with regard to alloy rivets, it was difficult to apply to the heel in terms of strength due to cracks at the heel when tableted for a long time.
Although other surface treatments such as diamond-like carbon (DLC) and Niuroy 96 treatment were also attempted on SKS2 杵, satisfactory results could not be obtained.
[0035]
[Example 2]
A chrome doppe-N coating is applied to a cage made of a conventional alloy tool (hereinafter referred to as SKS2) according to the above-mentioned means known per se (see Mold Technology Vol. 8 No. 5 (April 1993) pp. 70-78). A cocoon (hereinafter also simply referred to as Example 杵) was obtained. The releasability of the above-mentioned Example cocoon was compared with the cocoon produced with SKS2, the cocoon produced with SUS440C, and the cocoon with diamond-like carbon (DLC) coating on SKS2. The releasability of the cocoons is determined by the occurrence of tablets (hereinafter referred to as imprinting defects) where the tableting powder adheres to the surface of the candy that occurs during tableting and does not form a clear marking on the tablet surface, and the Evaluation was performed based on the occurrence of adhesion (hereinafter referred to as flaw adhesion). In the tableting, a tableting powder having the following formulation containing D-mannitol was used.
[0036]
[0037]
The results are as shown in Table 3. SKS2 杵, SUS440C 杵 and DLC coated 杵 had imprinting defects from the beginning of tableting and became unable to be tableted, whereas Example 杵 was also in the initial and final stages of tableting. The occurrence of imprinting defects was not observed, and the occurrence of tableting powder adhering to the surface of the punch was not observed.
[0038]
[Table 3]
[0039]
Example 3
Lansoprazole fine granules containing 30 parts by weight of lansoprazole (manufactured by the method described in Japanese Patent Application No. 11-135177) 270 parts by weight, D-mannitol 204 parts by weight, L-HPC-33 30 parts by weight, Theolas KG FIG. 1 shows a tableting powder obtained by mixing 30 parts by weight of 801, 15 parts by weight of crospovidone, 3 parts by weight of anhydrous citric acid, 9 parts by weight of aspartame, 3 parts by weight of Strobery-D and 6 parts by weight of magnesium stearate. Tableting was performed with the indicated tableting machine. The soot material and the soot surface treatment are the same as those in Example 1. The tableting conditions were a tableting outer diameter of 7 mmφ, a weight of 180 mg / tablet, and a tableting pressure of 0.57 ton. Table 4 below shows the results of scissors material / surface treatment and 20000 tablets / compressed tablets.
[0040]
[Table 4]
[0041]
【The invention's effect】
The punch made of chrome doppe-N coating on the alloy tool steel of the present invention exhibits excellent corrosion resistance and mold release in tableting of a preparation containing an acidic substance, and tableting of a preparation containing an adhesive substance Provides a tableting which is excellent in releasability and suitable for stable industrial production.
[0042]
[Brief description of the drawings]
FIG. 1 is a schematic cross-sectional view of a rotary tableting machine using a punch according to an embodiment of the present invention.
[Explanation of symbols]
1 ……………… Rotary tablet press,
2 ……………… Turntable,
3 ……………… Mus,
3a …………… Mole hole,
4 ……………… Upper,
5 ……………… Upper holding board,
6 ……………… Shimojo,
7 ……………… The lower arm holding board,
8 ……………… Upper guide rail,
9 ……………… Shimojo guide rail,
10 ......... Tablet powder
Claims (14)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000002652A JP4799720B2 (en) | 1999-01-29 | 2000-01-11 | Tableting punch with coating treatment |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1999020894 | 1999-01-29 | ||
| JP2089499 | 1999-01-29 | ||
| JP11-188242 | 1999-07-01 | ||
| JP11-20894 | 1999-07-01 | ||
| JP18824299 | 1999-07-01 | ||
| JP1999188242 | 1999-07-01 | ||
| JP2000002652A JP4799720B2 (en) | 1999-01-29 | 2000-01-11 | Tableting punch with coating treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001071189A JP2001071189A (en) | 2001-03-21 |
| JP4799720B2 true JP4799720B2 (en) | 2011-10-26 |
Family
ID=27283212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000002652A Expired - Lifetime JP4799720B2 (en) | 1999-01-29 | 2000-01-11 | Tableting punch with coating treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4799720B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5095924B2 (en) * | 2005-05-16 | 2012-12-12 | 芙蓉工業株式会社 | Tablet punch or mortar |
| JP4625882B2 (en) * | 2005-07-19 | 2011-02-02 | Dowaサーモテック株式会社 | Tableting punch |
| JP5117023B2 (en) * | 2006-09-19 | 2013-01-09 | ライオン株式会社 | Tablet manufacturing method and tableting punch |
| US20100330385A1 (en) | 2008-02-08 | 2010-12-30 | Kazuo Sawaguchi | Method for tableting surface treatment of tableting punch or die, punch or die subjected to surface treatment by this method, and tablet formed by using this tableting punch or die |
| KR102167931B1 (en) * | 2020-04-06 | 2020-10-20 | 김한철 | Method for producing functional health food |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2545258B2 (en) * | 1987-04-27 | 1996-10-16 | 協和醗酵工業株式会社 | Compression molding machine |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| JP4289688B2 (en) * | 1996-04-03 | 2009-07-01 | 武田薬品工業株式会社 | Oxazole derivatives, production methods and agents thereof |
-
2000
- 2000-01-11 JP JP2000002652A patent/JP4799720B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001071189A (en) | 2001-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8357396B2 (en) | Intrabuccally rapidly disintegrating tablet and a production method of the tablets | |
| JPWO2012118180A1 (en) | Layered tablet and method for producing the same | |
| EP0879049A1 (en) | Process to prepare soluble delivery systems using volatile salts | |
| JP2006527184A5 (en) | ||
| WO2004064810A1 (en) | Tablet quickly melting in oral cavity | |
| EP1147879B1 (en) | Compressing mallet with coating treatment | |
| US6432534B1 (en) | Process for the production of tablets and tablets | |
| JP4799720B2 (en) | Tableting punch with coating treatment | |
| WO1999059552A1 (en) | Regulated release preparations | |
| JPWO2003103713A1 (en) | Quick disintegrating tablet and method for producing the same | |
| JP2002001593A (en) | Punch and die for tablet machine | |
| Saniocki | New insights into tablet sticking: characterization and quantification of sticking to punch surfaces during tablet manufacture by direct compaction | |
| JP2003210553A (en) | Preparation molding device and preparation | |
| HU219341B (en) | Process for producing pressed, moulded, delayed release dose units and dose units thus produced | |
| JP6446413B2 (en) | Ibuprofen sodium tablet and method for producing pharmaceutical composition containing ibuprofen sodium | |
| JP2002360666A (en) | Tableting pestle-mortar using cobalt alloy | |
| Nizami et al. | Recent Advancement and Challenges in Bilayer Tablet Technology: An Overview | |
| JP5117023B2 (en) | Tablet manufacturing method and tableting punch | |
| JP4625882B2 (en) | Tableting punch | |
| US20100144711A1 (en) | Pharmaceutical composition for oral administration | |
| EP4487839A1 (en) | Pharmaceutical dosage form comprising trientine tetrahydrochloride, and method for preparing the same | |
| Sahoo | Tablets | |
| RU2253451C1 (en) | Antiallergic drug | |
| RU2585378C1 (en) | Solid dosage form for oral administration containing combination of vildagliptin and gliquidone | |
| JP2014031332A (en) | Method of manufacturing compact on which mark is applied |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060626 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090204 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100420 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100618 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101228 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110802 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110803 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4799720 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |